Two years after CRL, Intercept will meet with FDA later this month to discuss new analysis of NASH drug

Intercept Pharmaceuticals is meeting with the FDA later this month in the biotech’s bid to resubmit its drug, obeticholic acid or OCA, for liver scarring due to NASH.